^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EU210

    i
    Other names: EU210, WTiNT, WiT&T, WTiNT T cell therapy
    Associations

    News

    Trials
    Company:
    Eutilex
    Drug class:
    CD137 agonist, Wilms tumor 1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rα CD8 T cells. (PubMed, Nat Commun)
    Mechanistically, the anti-tumor effect of IL-18Rα subset is mediated by IL-18 signaling and TCR-MHC I interaction. This study highlights the clinical relevance of CD4 in ACT and provides insights regarding the immunological nature of anti-CD4 treatment, which enhances anti-tumor response of CD8 T cells.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL18 (Interleukin 18)
    |
    EU210